版本:
中国

BRIEF-Ra Pharmaceuticals looks forward to advance oral small molecule C5 inhibitor program

Nov 30 Ra Pharmaceuticals Inc -

* "We also look forward to advancing our oral small molecule C5 inhibitor program through early development and toward an ind"

* "We are eager to initiate our phase 2 program in PNH patients in Q1 of 2017" Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐